Artivion, Inc. (NYSE:AORT) Shares Sold by Bank of America Corp DE

Bank of America Corp DE cut its position in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 404,006 shares of the company's stock after selling 9,611 shares during the quarter. Bank of America Corp DE owned approximately 0.96% of Artivion worth $11,551,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Smartleaf Asset Management LLC grew its holdings in Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after buying an additional 786 shares during the period. R Squared Ltd acquired a new stake in shares of Artivion in the fourth quarter worth approximately $39,000. Arcadia Investment Management Corp MI purchased a new stake in Artivion in the fourth quarter valued at approximately $43,000. Venturi Wealth Management LLC purchased a new stake in Artivion in the fourth quarter valued at approximately $78,000. Finally, KBC Group NV increased its position in Artivion by 80.4% during the fourth quarter. KBC Group NV now owns 2,813 shares of the company's stock worth $80,000 after purchasing an additional 1,254 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.

Artivion Stock Up 0.0%

Shares of NYSE AORT traded up $0.01 on Wednesday, hitting $29.22. The company had a trading volume of 41,502 shares, compared to its average volume of 458,606. The firm has a market capitalization of $1.25 billion, a P/E ratio of -1,460.90 and a beta of 1.54. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $32.33. The business has a 50 day moving average of $25.32 and a two-hundred day moving average of $27.35.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.06). The firm had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. As a group, equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Activity

In other Artivion news, Director Anthony B. Semedo sold 2,600 shares of the company's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $28.47, for a total transaction of $74,022.00. Following the sale, the director now owns 33,059 shares in the company, valued at $941,189.73. This represents a 7.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jean F. Holloway sold 18,020 shares of Artivion stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total value of $425,452.20. Following the completion of the transaction, the senior vice president now owns 197,184 shares of the company's stock, valued at approximately $4,655,514.24. The trade was a 8.37% decrease in their position. The disclosure for this sale can be found here. Insiders sold 65,414 shares of company stock worth $1,716,731 over the last ninety days. Corporate insiders own 7.60% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on AORT shares. Stifel Nicolaus lowered their price objective on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, February 25th. Citizens Jmp raised Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. JMP Securities restated a "market outperform" rating and issued a $33.00 price objective on shares of Artivion in a report on Tuesday, May 6th. Finally, Needham & Company LLC reissued a "buy" rating and set a $32.00 target price on shares of Artivion in a research report on Tuesday, May 6th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $31.40.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.